Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells

Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML

(2018) Steven Blotner et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

(2017) Veronica Tisato et al.   Journal of Hematology & Oncology

When the guardian sleeps: Reactivation of the p53 pathway in cancer

(2017) Olaf Merkel et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

Recent progress in development of siRNA delivery vehicles for cancer therapy

(2016) Hyun Jin Kim et al.   ADVANCED DRUG DELIVERY REVIEWS

RISC assembly: Coordination between small RNAs and Argonaute proteins

(2016) Hotaka Kobayashi et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)

(2016) Frank Herting et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

(2016) Christian Lehmann et al.   Journal of Hematology & Oncology

Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting

(2016) F Wachter et al.   ONCOGENE

Clinical Overview of MDM2/X-Targeted Therapies

(2016) Andrew Burgess et al.   Frontiers in Oncology

Targeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy

(2015) Marsha Pellegrino et al.   CANCER RESEARCH

5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53

(2015) Birce Akpinar et al.   Oncotarget

p53 as a target for the treatment of cancer

(2014) Michael J. Duffy et al.   CANCER TREATMENT REVIEWS

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy

(2012) Q. Li et al.   CLINICAL CANCER RESEARCH

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

MDM4 is a key therapeutic target in cutaneous melanoma

(2012) Agnieszka Gembarska et al.   NATURE MEDICINE

Enhanced specificity of HPV16 E6E7 siRNA by RNA–DNA chimera modification

(2011) K Yamato et al.   CANCER GENE THERAPY

Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells

(2010) Shinji Endo et al.   CANCER SCIENCE

The p53 orchestra: Mdm2 and Mdmx set the tone

(2010) Mark Wade et al.   TRENDS IN CELL BIOLOGY

Regulation of MDMX Expression by Mitogenic Signaling

(2008) D. M. Gilkes et al.   MOLECULAR AND CELLULAR BIOLOGY

E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines

(2008) M Kitagawa et al.   ONCOGENE